Immuneering Corporation

What they do

Immuneering develops oral small molecule Deep Cyclic Inhibitors that target core signaling pathways such as MAPK, aiming to improve durability and tolerability versus chronic targeted therapies. Its lead candidate, atebimetinib (IMM-1-104), is a once-daily MEK inhibitor being studied in the Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic ductal adenocarcinoma in combination with modified gemcitabine/nab-paclitaxel. A second clinical-stage candidate, envometinib (IMM-6-415), and earlier research programs are also in development. Historically the company also provided computational biology analyses to pharmaceutical and biotechnology partners.

Revenue drivers

• Atebimetinib (IMM-1-104) — Lead clinical-stage asset; no product revenue to date, with value tied to the Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer.
• Envometinib (IMM-6-415) — Additional clinical-stage Deep Cyclic Inhibitor; earlier-stage than atebimetinib and not yet a revenue source.
• Collaboration and computational biology services — Historically the only reported revenue; annual revenue fell from $2.3M in 2020 and $2.1M in 2021 to $316,952 in 2022 and $0.00 in 2023.

Recent performance

Second quarter 2026 ended with $182.7 million in cash, cash equivalents and marketable securities, which the company says supports runway into 2029. In June 2026 the company dosed the first patient in the Phase 3 MAPKeeper 301 trial, with more than 30 study locations posted to date. Updated Phase 2a data as of an April 24, 2026 cutoff showed 17.3 month median overall survival in 55 first-line pancreatic cancer patients dosed at 320 mg atebimetinib plus mGnP, versus 8.5 months reported from third-party MPACT standard-of-care data, with median follow-up of 11.6 months. Median progression-free survival was 8.3 months, ORR was 36% (18/50) and DCR was 82% (41/50); 84% of evaluable patients were weight stable or gained weight at three months. Annual net loss was $56.0M in 2025 and operating cash flow was negative $45.3M.

Strategy

The company's primary priority is executing MAPKeeper 301, a global randomized open-label registrational Phase 3 trial of atebimetinib plus mGnP in approximately 510 first-line metastatic PDAC patients, with overall survival as the primary endpoint. It plans to present further circulating tumor DNA data on acquired alterations in the second quarter of 2026 and updated survival data from over 50 first-line pancreatic patients in the first half of 2026. It also plans to dose the first patient in a trial of atebimetinib plus Libtayo in non-small cell lung cancer in the second half of 2026. Immuneering continues to invest in its DCI platform, which relies on bioinformatics and proprietary humanized 3D tumor modeling. In June 2026 it appointed Andrew Gengos as Chief Financial Officer to oversee financial strategy, capital allocation, investor relations, business development and corporate development.

Risks

• No approved products — The company has no products approved for commercial sale and has not generated any product revenue, so it has no commercial-stage cash flow.
• Registrational trial risk — It has not completed any registrational clinical trials, and MAPKeeper 301's overall survival endpoint may not replicate the single-arm Phase 2a results.
• Cross-trial comparison limitations — The Phase 1/2a trial does not include a head-to-head comparison against other agents, and the company cautions that comparisons with the third-party MPACT standard-of-care data should be made with caution.
• Cash burn and dilution — Operating cash flow was negative $45.3M in 2025, and funding MAPKeeper 301 in approximately 510 patients may require additional capital beyond the stated runway into 2029.

Outlook

Management said the Phase 3 MAPKeeper 301 trial is underway with patients being dosed and over 30 study locations posted. It expects to report further updated survival data from over 50 first-line pancreatic cancer patients in the first half of 2026, present additional circulating tumor DNA data in the second quarter of 2026, and dose the first patient in a planned atebimetinib plus Libtayo trial in non-small cell lung cancer in the second half of 2026. It reported $182.7 million in cash, cash equivalents and marketable securities at June 30, 2026, with anticipated runway into 2029.